Product Introduction
Bioactivity


英文名: Ecopipam

描述: Ecopipam (UNII-0X748O646K) 是一种有效的、选择性、具有口服活性的多巴胺 D1/D5 受体拮抗剂，Ki 值分别为 1.2 nM 和 2.0 nM。Ecopipam 对 D2、D4、5-HT 和 α2a 受体 (Ki=0.98，5.52，0.08 和 0.73 μM) 显示出超过 40 倍的选择性。Ecopipam 可用于精神分裂症、可卡因成瘾和肥胖症的研究。

体外活性: Ecopipam (2 μM) 完全消除了在分离的皮质海马形成中[2]，多巴胺 (10 μM) 的促癫痫效应。

体内活性: Ecopipam (0.003-0.3 mg/kg; a single s.c.) abolishes Nicotine-induced enhancement of a sensory reinforcer in adult rats[3]. Ecopipam (10, mg/kg, oral administration) antagonizes Apomorphine-induced stereotypy in rats[4]. Ecopipam (5 and 10 μM, perfusion, 1 μL/min) reversibly and dose-dependently decreases acetylcholine release in the rat striatum[5].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

关键字: Ecopipam

相关产品: Triflupromazine hydrochloride | Clebopride malate | D-tetrahydropalmatine | Xaliproden hydrochloride | Flunarizine dihydrochloride | Syrosingopine | Oxolinic acid | Tipepidine hydrochloride | PZ-1190 | BMY 7378 dihydrochloride

相关库: Anti-Neurodegenerative Disease Compound Library | Neurotransmitter Receptor Compound Library | ReFRAME Related Library | Anti-Cancer Drug Library | Clinical Compound Library | Membrane Protein-targeted Compound Library | Neuronal Signaling Compound Library | Anti-Cancer Clinical Compound Library | GPCR Compound Library